Teva Tells 3rd Circ. Other Rulings Back Lamictal Dismissal
Teva Pharmaceutical Industries Ltd. urged the Third Circuit on Tuesday not to revive a suit over a no-authorized-generic deal between the company and GlaxoSmithKline PLC regarding Lamictal, claiming that dismissals in...To view the full article, register now.
Already a subscriber? Click here to view full article